FDA Drug Approval & Pharmaceutical Regulation

The FDA's drug approval system determines which medicines Americans can legally access — and at what price. Under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Chapter 9), a new drug must demonstrate safety and efficacy through a three-phase clinical trial process before receiving FDA approval, a process that typically takes 10–15 years and costs $1–2 billion per approved drug on average. The Hatch-Waxman Act (1984) created the generic drug pathway that allows generic manufacturers to reference the original drug's safety data after patents expire, which is why generics can enter at 20–30% of brand-name prices. FDA approves roughly 50–55 novel drugs and 800–1,000 generic drugs annually. The approval system's design — expensive for innovators, enabling for generics — is the mechanism behind both the high prices of new specialty drugs and the low prices of common generics. Understanding where a drug is in its patent and exclusivity lifecycle explains more about its price than almost any other single factor.

Current Law (2026)

Legal Authority

• 21 U.S.C. § 301 — Short title (Federal Food, Drug, and Cosmetic Act — FDCA)
• 21 U.S.C. § 331 — Prohibited acts (introduction of adulterated or misbranded food/drugs/devices/cosmetics into interstate commerce; failure to register establishments; promotion of unapproved uses)
• 21 U.S.C. § 341 — Definitions and standards for food (Secretary prescribes definitions and standards of identity, quality, and fill of container — establishes what a food product must contain to be sold under a given name)
• 21 U.S.C. § 342 — Adulterated food (food is adulterated if it contains poisonous substances, unsafe food additives, filth, or is prepared in insanitary conditions; see Food Safety Regulation for full treatment)
• 21 U.S.C. § 343 — Misbranded food (food is misbranded if labeling is false or misleading, fails required nutrition labeling, or makes unauthorized health claims)
• 21 U.S.C. § 348 — Food additives (no food additive shall be used unless it conforms to a regulation prescribing conditions of safe use, or is generally recognized as safe — GRAS)
• 21 U.S.C. § 350d — Registration of food facilities (domestic and foreign facilities that manufacture, process, pack, or hold food for U.S. consumption must register with FDA)
• 21 U.S.C. § 350h — Produce safety (FSMA standards for growing, harvesting, packing, and holding produce — agricultural water, biological soil amendments, worker hygiene, domesticated and wild animals)
• 21 U.S.C. § 351-352 — Adulterated and misbranded drugs (drug is adulterated if it differs from compendial standards, is contaminated, not manufactured under GMP, or in a container composed of unsafe substances; drug is misbranded if labeling is false or misleading, lacks adequate directions for use, or lacks required information)
• 21 U.S.C. § 355 — New drug applications / NDAs (no person shall introduce a new drug unless an approved application is in effect; NDA must contain full reports of investigations demonstrating safety and effectiveness; FDA has 180 days to act; approval, approvable, or not-approvable letter; supplemental NDAs for changes)
• 21 U.S.C. § 355(j) — Abbreviated New Drug Applications / ANDAs (generic drugs: must demonstrate bioequivalence to reference listed drug; same active ingredient, route, dosage form, and strength; paragraph IV certifications for patent challenges; 180-day exclusivity for first generic filer)
• 21 U.S.C. § 356 — Expedited pathways (fast track, breakthrough therapy, accelerated approval, priority review; for serious conditions that fill an unmet medical need)
• 21 U.S.C. § 360 — Registration of drug establishments (every establishment manufacturing, preparing, propagating, compounding, or processing drugs must register with FDA annually; subject to inspection)
• 21 U.S.C. § 374 — Inspections (FDA authorized to inspect any factory, warehouse, establishment, or vehicle where drugs are manufactured, processed, packed, or held; records access; no advance notice required)
• 21 U.S.C. § 393 — FDA mission (protect public health by ensuring safety, efficacy, and security of drugs, biologics, devices, food, cosmetics; advance public health by expediting innovations)

Implementing Regulations (21 CFR)

• 21 CFR Part 312 — Investigational New Drug (IND) Application: the regulatory framework governing clinical investigation of new drugs in human subjects. No sponsor may administer an investigational drug to U.S. subjects without an active IND — Part 312 defines what the IND must contain, how FDA reviews it, and the ongoing obligations during a clinical program:

  • § 312.2 — Applicability: the IND requirement applies to any clinical investigation of a new drug (including a marketed drug being studied for a new indication or population) that will be used to support a future FDA approval; exemptions exist for lawful marketed drugs used in studies not intended to support an NDA if no unreasonable risk exists
  • § 312.20 — Requirement for an IND: any sponsor who intends to conduct a clinical investigation involving an investigational new drug must submit an IND to FDA before beginning; the IND becomes effective 30 days after FDA receives it unless FDA notifies the sponsor of a clinical hold within that period
  • § 312.21 — Phases of investigation: the IND framework defines three phases — Phase I (20–100 subjects, primarily safety and pharmacokinetics, typically healthy volunteers); Phase II (100–500 patients, preliminary evidence of efficacy and dose-response); Phase III (1,000–5,000 patients, definitive controlled trials establishing safety and efficacy for the intended indication); an IND may cover one or multiple phases
  • § 312.22 — FDA review standard: at the IND stage, FDA's primary objective is assessing whether subjects will be exposed to unreasonable risk — not whether the drug will prove effective; FDA may place an IND on clinical hold if there is an unreasonable risk of harm or if the IND is deficient; once Phase III is complete, the sponsor files an NDA with all accumulated data
  • § 312.23 — IND content: each IND submission must include FDA Form 1571 (administrative cover), an introductory statement and general investigational plan, an investigator's brochure (summary of drug information for investigators), clinical protocols for each study, chemistry/manufacturing/controls (CMC) information on the drug substance and product, pharmacology and toxicology data from preclinical studies, and a list of previous human experience; the IND must be updated with protocol amendments (§ 312.30) and annual reports (§ 312.33)
  • §§ 312.300–312.320 — Expanded access (compassionate use): these sections govern use of investigational drugs outside clinical trials for seriously ill patients — including individual patient expanded access (§ 312.310, the "compassionate use" pathway for a single patient when no comparable alternatives exist and potential benefit justifies risk), intermediate-size patient populations (§ 312.315, for multiple patients not in a trial), and treatment IND/protocol (§ 312.320, broader access during late-stage trials)
  • § 312.310(b) — Emergency use without prior FDA authorization: in life-threatening emergencies where there is no time for prior IND authorization, a licensed physician may administer an investigational drug with verbal FDA authorization; FDA must be notified within 15 business days; retrospective IND submission may be required

  The 30-day clock in Part 312 is one of the most important deadlines in drug development — it gives FDA time to review safety before first-in-human dosing but avoids indefinite delays; FDA can place the IND on clinical hold at any time during the program if safety signals emerge. The IND system creates a continuous FDA-sponsor relationship throughout drug development, with FDA able to require additional studies, restrict dosing, or halt trials through hold authority.

• 21 CFR Part 310 — New Drugs (37 sections — the foundational regulations defining which products require FDA approval as "new drugs" and setting special requirements for certain marketed drug categories):

  • § 310.100 — New drug status opinions: FDA issues new drug status opinions (now called "new drug applications policy statements") addressing whether specific marketed products require NDAs or are "generally recognized as safe and effective" (GRASE) and thus exempt from the NDA requirement; products that were on the market before June 25, 1938 (when the FDCA first required safety approvals) may be "grandfather" drugs not requiring NDAs; in practice, the grandfather categories are extremely narrow — FDA's position is that virtually all drug products require either an NDA or ANDA
  • § 310.200 — Prescription-exemption procedure: establishes that FDA can reclassify prescription-only drugs to OTC (non-prescription) status through the prescription-exemption rule; the OTC switch from Rx to OTC is one of the key policy tools making medications more accessible and lowering consumer costs; key examples include antihistamines (Claritin, Allegra, Zyrtec), proton pump inhibitors (Prilosec, Nexium), statins (debated but not yet approved), and most recently Narcan (naloxone)
  • § 310.305 — Adverse drug experience reporting for marketed drugs without approved NDAs: manufacturers, packers, and distributors of marketed prescription drugs without approved NDAs must maintain records of adverse drug experiences and submit periodic reports to FDA; this provision extends post-market pharmacovigilance requirements to the small subset of prescription drugs that predate the NDA system; ADR reports must be submitted quarterly for the first 3 years and annually thereafter, using the same format as NDA holders; failure to report known serious adverse events is a violation of 21 U.S.C. § 355
  • § 310.501 — Patient package inserts (PPIs) for oral contraceptives: every dispensing of an oral contraceptive must include a patient package insert in language understandable to lay patients; the PPI must describe: the product's benefits and risks, contraindications (pregnancy, smoking in women over 35, history of blood clots), warning signs of serious complications (stroke, thromboembolism, liver tumors), instructions for use, and what to do for missed doses; this was one of the first FDA-mandated patient information documents (finalized 1978) and became the model for the broader Medication Guide program
  • § 310.502 — Drugs accorded new drug status through rulemaking: certain drug products that were marketed without NDAs have been formally designated as "new drugs" requiring FDA approval through rulemaking; this provision covers products like certain cold medications, topical antiseptics, and contraceptive products that were marketed for years before FDA determined they require NDA approval; the rulemaking process is slow and contested, but § 310.502 allows FDA to enforce NDA requirements against historically grandfathered products when safety or efficacy concerns emerge

  Part 310's most significant practical impact today is its role in the OTC monograph system (OTC switch) and its adverse event reporting requirements for the diminishing number of legacy marketed drugs without approved NDAs. The Part 310 framework underpins FDA's authority to pull marketed drugs that have never been approved — using the "new drug" designation to require manufacturers to either submit NDAs or cease marketing. FDA's enforcement actions under Part 310 include major market withdrawals of combination cold products and certain topical antiseptics. Recent rulemakings: 74 FR 13113 (March 2009) — revised adverse event reporting requirements.

• 21 CFR Part 314 — New Drug Applications (NDA): content and format requirements for approval; clinical/nonclinical data, manufacturing information, labeling; FDA review standards; Abbreviated New Drug Applications (ANDAs) for generics — bioequivalence testing, Orange Book listings, patent certifications (Paragraph IV)

• 21 CFR Part 601 — Biologics License Applications (BLA): approval pathway for biological products (vaccines, blood products, gene therapy); biosimilar applications (351(k) pathway) under BPCIA

• 21 CFR Part 211 — Current Good Manufacturing Practice (cGMP) for Finished Pharmaceuticals: the mandatory quality system every drug manufacturer must maintain; FDA inspects manufacturing facilities for cGMP compliance as part of NDA/ANDA approval and on a routine basis; failure to comply is a basis for product recalls, warning letters, import alerts, and consent decrees:

  • § 211.1 — Scope: applies to all finished pharmaceuticals manufactured in the U.S. or imported for use in clinical trials or commercial distribution; includes prescription drugs, OTC drugs, and biologics regulated as drugs; does not cover bulk pharmaceutical chemicals (covered by Part 210)
  • § 211.100 — Written procedures: every production and process control procedure must be in writing; any deviation must be recorded and justified; a fundamental principle — oral instructions are not cGMP compliance; written procedures create the audit trail FDA inspectors examine
  • § 211.110 — In-process testing: manufacturers must sample and test drug products at various points in the production process to ensure batch uniformity and integrity; testing must be conducted according to written specifications; any result outside specification must be documented and investigated
  • § 211.113 — Microbiological contamination control: for sterile drug products, manufacturers must establish and validate aseptic manufacturing processes and routinely test for microbial contamination; for non-sterile products, total microbial count limits apply; objectionable organisms in any drug product must be investigated and corrected
  • § 211.130 / § 211.132 — Labeling and tamper-evident packaging: labeling operations must prevent mix-ups between products and batches (a major source of recalls); reconciliation of labels issued vs. used vs. destroyed required; all OTC products (except those sold behind pharmacy counters) must be in tamper-evident packaging that visibly indicates opening
  • § 211.137 — Expiration dating: every drug product must have an expiration date based on stability testing; the expiration date must appear on both the immediate container and the outer package; expiration dating requirements apply to all drug products, including controlled substances
  • §§ 211.160–211.165 — Laboratory controls: an independent laboratory (or quality control unit) must test each batch and approve or reject it before distribution; test methods must be validated; out-of-specification (OOS) results must be investigated; FDA has issued guidance on OOS investigations and has cited insufficient OOS investigation as a major warning letter finding
  • § 211.166 — Stability testing: manufacturers must have a written stability testing program; testing must be conducted in containers representative of the marketed product; stability data must support the expiration date assigned; post-approval stability testing must continue to confirm that product retains potency, quality, and purity through expiration

  cGMP failures are among the most serious FDA enforcement problems — a manufacturing defect can affect an entire production lot, potentially exposing thousands of patients to subpotent, superpotent, contaminated, or mislabeled drugs. FDA's enforcement ladder runs from informal observations during inspections, to Form 483 observations, to warning letters, to consent decrees requiring independent oversight of manufacturing operations, to seizure and injunction. Import alerts block imported drugs from manufacturers with unresolved cGMP violations from entering the U.S. market.

• 21 CFR Part 316 — Orphan drugs: designation criteria (fewer than 200,000 affected), clinical superiority, 7-year marketing exclusivity, tax credits for clinical testing costs

• 21 CFR Part 356 — Expedited programs: priority review (6-month target), accelerated approval (surrogate endpoints), fast track (rolling review), breakthrough therapy (intensive FDA guidance) — codified criteria and procedures

• 21 CFR Part 201 — Drug Labeling: the comprehensive framework governing what must appear on every prescription and over-the-counter drug label and package insert in the United States. Six subparts cover the full spectrum:

  • § 201.1 — Manufacturer/distributor identity required on all finished drug labels; § 201.2 — National Drug Code (NDC) number (requested but not mandatory); § 201.17 — expiration date placement on both immediate container and outer package; § 201.18 — lot number as complete manufacturing history key
  • § 201.20 — Required warning for FD&C Yellow No. 5 (tartrazine) — the dye causes allergic-type reactions (including asthma) in some patients, so any drug containing it must disclose this specifically; § 201.21 — phenylalanine warning for aspartame-containing drugs (critical for patients with phenylketonuria); § 201.22 — sulfite warning for sulfite-containing drugs (risk of severe allergic reactions including anaphylaxis)
  • § 201.23 — Required pediatric studies: FDA may require manufacturers to conduct pediatric studies for drugs used in substantial numbers of pediatric patients, even after approval; establishes the Pediatric Research Equity Act framework
  • § 201.56 / § 201.57 — Prescription drug labeling format and content (the "PI" or package insert): the full prescribing information must contain a structured summary — Highlights of Prescribing Information (first page: boxed warning if applicable, recent major changes, indications and usage, dosage and administration, dosage forms/strengths, contraindications, warnings/precautions, adverse reactions, drug interactions, use in specific populations, then full PI sections in numbered order). The boxed warning ("black box") — required when "there is reasonable evidence of an association of a serious hazard with a drug" — is printed prominently at the top of the Highlights in a box; examples: SSRIs (suicidality in children/adolescents), opioids (addiction/overdose/respiratory depression, interaction with CNS depressants), fluoroquinolones (tendinitis/rupture, peripheral neuropathy), certain antibiotics and antivirals (serious adverse effects requiring monitoring)
  • § 201.63 — OTC pregnancy/breastfeeding warning: all systemic OTC drugs must carry "If pregnant or breast-feeding, ask a health professional before use" unless specifically exempted
  • § 201.66 — Over-the-counter Drug Facts panel: the standardized format (analogous to the Nutrition Facts panel for food) required on all OTC drug products since 2002. The Drug Facts box must list in sequence: Active ingredient(s) with amount and purpose; Uses (indications — plain-English list of conditions addressed); Warnings (do not use if, ask a doctor if, ask a doctor or pharmacist if, when using, stop use and ask a doctor if, keep out of reach of children, pregnancy/breastfeeding); Directions (dosage by age group); Other information (storage, sodium content if ≥5 mg/dose); Inactive ingredients (alphabetical order). Format requirements include minimum type size and organization rules designed to make the information scannable in any lighting condition.

  The distinction between Rx and OTC labeling is enforced by law: a drug is prescription-only if it is habit-forming, requires professional diagnosis to use safely, or has a potential for harm requiring prescriber supervision. OTC drugs are those "generally recognized as safe and effective" for self-diagnosis and self-treatment under adequate directions for use on the label.

• 21 CFR Part 320 — Bioavailability and Bioequivalence Requirements (standards for demonstrating that generic drugs are bioequivalent to reference listed drugs; 19 sections)

• 21 CFR Part 11 — Electronic Records; Electronic Signatures: one of the most operationally impactful FDA regulations for the pharmaceutical industry — it governs when and how electronic records and electronic signatures can substitute for traditional paper records and handwritten signatures in FDA-regulated activities:

  • § 11.1 — Scope: Part 11 applies to all records (and their signatures) that the FDCA requires to be maintained or submitted to FDA — batch manufacturing records, stability records, clinical trial data, laboratory records, quality system documentation, and adverse event reports; companies that choose to create and maintain these records electronically must comply with Part 11 requirements; companies that maintain paper records are not subject to Part 11 but cannot submit electronic versions to FDA without Part 11 compliance
  • § 11.10 — Controls for closed systems: electronic record systems that restrict access to authorized users must implement: (1) validation of the system to ensure accuracy, reliability, and consistent performance; (2) the ability to generate accurate and complete copies of records; (3) record protection to ensure that records are not altered or deleted except through authorized modifications; (4) access limitation through use of authority checks (passwords, biometrics, or other methods); (5) computer-generated, time-stamped audit trails that independently record all operator entries and actions — the audit trail cannot be deactivated and must be retained as long as the records themselves
  • § 11.30 — Controls for open systems (internet-connected): all § 11.10 requirements apply plus additional encryption and digital signature requirements to ensure authenticity and integrity when records are transmitted over open communication channels
  • § 11.50 — Signature manifestations: every signed electronic record must contain the signer's printed name, the date and time of signing, and the meaning of the signature (review, approval, author) — preventing generic electronic signatures that don't capture what the signer affirmed
  • § 11.100 — Electronic signature uniqueness: each electronic signature must be unique to one individual and may not be reused or reassigned; before any electronic signature is established, the organization must certify in writing to FDA that electronic signatures are the legally binding equivalent of handwritten signatures; this certification is a one-time filing
  • § 11.200 — Signature components: electronic signatures not based on biometrics must use at least two distinct identification components (e.g., ID code + password); if a person signs multiple records in a single session, subsequent signings after the first can use a single component; if signing in separate sessions or on different occasions, all components must be used

  21 CFR Part 11 compliance is a prerequisite for using electronic systems in FDA-regulated environments — Laboratory Information Management Systems (LIMS), Electronic Lab Notebooks (ELNs), Manufacturing Execution Systems (MES), Clinical Data Management Systems, and Quality Management Systems must all be Part 11-compliant to support FDA inspection. The most commonly cited violations in FDA warning letters are: lack of audit trail capability, inadequate access controls, and failure to validate computer systems. The FDA issued a guidance in 2003 narrowing its enforcement interpretation to focus on the most risk-relevant aspects (audit trails, access controls, validation); this guidance reduced compliance burden but did not change the regulatory text. Recent rulemakings: 69 FR 71655 (December 2004) — FDA guidance narrowing enforcement; 79 FR 71253 (December 2014) — updated references for electronic submissions.

• 21 CFR Part 355 — Anticaries Drug Products for Over-the-Counter Human Use: the OTC monograph governing fluoride-containing toothpaste, rinses, and gels — the most widely used non-prescription drugs in the United States, present in virtually every bathroom. Part 355 defines which fluoride active ingredients and concentrations are GRASE (generally recognized as safe and effective) for cavity prevention without a prescription:

  • § 355.10 — Active ingredients: approved fluoride active ingredients for dentifrices (toothpastes/gels/powders) include sodium fluoride (850–1,150 ppm total fluorine; 0.188–0.254%), sodium monofluorophosphate (MFP — 0.76–1.14% in dentifrices), and stannous fluoride (0.454% stabilized in dentifrices, 0.1% in treatment rinses); for treatment rinses, approved options include sodium fluoride solutions (0.02% NaF daily rinse; 0.09% NaF weekly rinse) and acidulated phosphate fluoride (APF) solutions; the concentration ranges are calibrated to provide therapeutic fluoride ion delivery to tooth enamel while staying below toxicity thresholds for incidental ingestion
  • § 355.20 — Packaging conditions: fluoride toxicity drives mandatory package size limits — dentifrice packages may not contain more than 276 mg total fluorine per package (equivalent to roughly 4–5 oz of standard-strength toothpaste); preventive treatment gels and rinses may not contain more than 120 mg total fluorine per package; these limits prevent a child who ingests an entire tube or bottle from receiving a toxic dose; exception for professional-use-only products labeled accordingly; all fluoride powders must be in tight containers to prevent moisture contamination and clumping
  • § 355.50 — Labeling requirements: the label must identify the product using standardized terms ("anticavity fluoride toothpaste," "fluoride treatment rinse," etc.); the indication must read "Aids in the prevention of dental cavities [or decay/caries]"; required warnings include "Keep out of reach of children under 6 years of age" and "If more than used for brushing is accidentally swallowed, get medical help or contact a Poison Control Center right away"; directions must specify age-appropriate amounts (pea-sized amount for children 2–6); children under 2 require physician consultation
  • § 355.60 — Professional-use labeling: products for dental office or professional use only (such as 1.1% sodium fluoride prescription-strength toothpaste or 2% NaF treatment rinses) may be labeled under different requirements and are exempt from the package size limits; these products are typically dispensed only by dental professionals and are not available OTC

  The fluoride OTC monograph framework under Part 355 is the regulatory basis for the ubiquity of fluoride toothpaste in the U.S. market — since the 1960 ADA Seal of Acceptance for Crest and FDA's subsequent OTC monograph finalization, fluoride dentifrices have become standard of care for cavity prevention. The 276 mg total fluorine package limit has been a point of compliance scrutiny for travel-size and multi-pack products. The CARES Act of 2020 (21 U.S.C. § 355h) reformed the OTC monograph system, allowing FDA to update OTC monographs through administrative orders rather than notice-and-comment rulemaking — Part 355 may be revised under this streamlined process. Recent rulemakings: 88 FR 45066 (July 2023) — FDA clarified OTC monograph applicability for certain fluoride product formats.

• 21 CFR Part 208 — Medication Guides for Prescription Drug Products: a parallel patient-information system that sits alongside the professional labeling framework of Parts 201 and 310. Where Part 201 prescribing information is written for clinicians, Medication Guides are FDA-approved patient information documents written in plain English for patients:

  • § 208.1 — Applicability: Part 208 applies to outpatient prescription drugs for which FDA determines that printed patient labeling could help prevent serious adverse effects, patient decisions based on serious side effects could affect safe use, or patient adherence to directions is essential for effectiveness; FDA makes this determination drug-by-drug and lists the products in the agency's Medication Guide database; examples include isotretinoin (Accutane), clozapine, warfarin, all antidepressants (for suicidality warning), and all opioid analgesics
  • § 208.20 — Content and format requirements: every Medication Guide must be written in plain English understandable to lay patients, non-promotional, and scientifically accurate; it must not conflict with the professional labeling required under § 201.57 but may present the information differently; FDA reviews and approves the Medication Guide as part of the drug approval process; required elements include: what the drug is used for, important safety information (boxed warning content in patient language), possible serious side effects, what to do if side effects occur, and how to take the drug correctly
  • § 208.24 — Distribution requirements: manufacturers and distributors must provide Medication Guides to dispensing pharmacies in sufficient numbers to give to every patient who receives the drug, OR must enter into agreements with dispensers to reproduce the Guides on demand; dispensers (pharmacies) must give a Medication Guide to every patient at each dispensing — including refills — unless the patient affirmatively declines in writing; for repackaging or sample distribution, distributors must include Guides or ensure the prescriber has Guides available
  • § 208.26 — Exemptions and deferrals: FDA may grant an exemption or deferral from the Medication Guide requirement if FDA determines the Guide is inapplicable (e.g., the drug is used only in inpatient settings where providers monitor administration), is unnecessary for safe use, or would be contrary to the best interests of patients; exemptions must be individually requested and FDA-granted — the manufacturer cannot self-exempt

  The Medication Guide requirement fills a critical gap: professional prescribing information is written at a medical school reading level and typically runs 20+ pages, making it inaccessible for patient decision-making. Medication Guides — written at an 8th-grade reading level and capped at a few pages — communicate the most important safety information in actionable terms ("Do not stop taking this medicine without talking to your doctor" rather than "Abrupt discontinuation may precipitate withdrawal syndrome"). FDA has expanded the Medication Guide program significantly: as of 2026, several hundred drug products require Guides, and the complete list is maintained in the Orange Book. The requirement that pharmacies distribute Guides at every dispensing creates a nationwide point-of-care patient safety system. No major rulemakings since the original 2000 final rule (65 FR 44446) — the program has grown through FDA's drug-by-drug labeling decisions rather than regulatory amendments.

• 21 CFR Part 203 — Prescription Drug Marketing: the implementing regulations for the Prescription Drug Marketing Act of 1987 (PDMA), which prohibits the reimportation of U.S.-manufactured prescription drugs (except by the original manufacturer), regulates the distribution of drug samples to licensed practitioners, and requires wholesale drug distributors to be licensed by their state. Part 203 addresses gray market drug diversion, counterfeit samples, and wholesale distribution practices that were identified as significant drug safety risks in the mid-1980s. Key provisions:

  • § 203.10 — Reimportation restrictions: no U.S.-manufactured prescription drug that was exported may be reimported except by the original manufacturer; reimportation by anyone else — wholesalers, pharmacies, individuals — is prohibited regardless of whether the drug left the U.S. legitimately; this is the regulatory provision at the center of the drug reimportation policy debate: FDA's enforcement authority under § 203.10 is the technical basis for the agency's long-standing position that importation of drugs by U.S. pharmacies and wholesalers from Canada or other countries violates federal law (even if FDCA § 801(d)(1) would technically permit it); the HHS Secretary retains discretionary authority under § 801(d)(1) to certify reimportation as safe, which the Biden HHS exercised in 2024 for Florida's wholesale importation program
  • § 203.11 — Emergency reimportation: an application for reimportation may be submitted to the FDA district office when the drug is needed to provide emergency medical care and a comparable product is unavailable; FDA may approve emergency reimportation case-by-case under defined criteria
  • § 203.20 — Drug sample sales restrictions: no person may sell, purchase, or trade any prescription drug sample; drug samples are intended only for demonstration to licensed practitioners and are not part of the commercial distribution chain; sale of drug samples (including by hospital employees, physicians' office staff, or wholesalers) is a criminal violation of the PDMA; the restriction addresses the prior practice of samples being diverted into secondary drug markets
  • § 203.30 — Drug sample distribution requirements: pharmaceutical manufacturers may distribute free samples of prescription drugs to licensed practitioners (physicians, dentists, NPs, PAs with prescriptive authority) and to pharmacies of hospitals and health care entities that request them; the requesting practitioner must sign a written request acknowledging receipt; each request must specify the drug name, strength, and quantity; manufacturers must maintain records of all sample requests and distributions for 3 years; these records are subject to FDA inspection
  • § 203.31 — Drug sample storage: practitioners receiving samples must store them under appropriate conditions; misbranded or adulterated samples must be returned or destroyed; samples must not be dispensed to patients (they may be provided but not sold or counted as part of the patient's prescription fill); the prohibition on charging patients for samples is absolute
  • § 203.37 — Audit and reconciliation: manufacturers must conduct periodic audits of drug sample inventories held by sales representatives; the representative must maintain a sample inventory, a record of all samples received and distributed, and reconcile the physical count with records; discrepancies must be investigated and reported to the manufacturer; missing samples (lost, stolen, or unaccounted for) must be reported to FDA if more than a specified quantity is missing
  • §§ 203.50–203.53 — Wholesale distributor licensing: any wholesale distributor of prescription drugs must be licensed by the state where it operates; Part 203 sets minimum standards for state licensing programs — requiring that distributors have a physical place of business, adequate storage conditions, minimum age for personnel, and that key personnel have no criminal convictions for drug distribution offenses; distributors must provide a statement of origin with each prescription drug delivery documenting the chain of custody from the original manufacturer

  The reimportation provisions of Part 203 remain among the most politically contested drug safety regulations. Congress has repeatedly debated permitting wholesale drug reimportation from Canada and the EU to reduce prices; the PDMA's § 10 restrictions have blocked this absent HHS certification. Florida became the first state to receive HHS approval for a wholesale reimportation program under § 801(d)(1) in January 2024, importing drugs from Canadian suppliers; the program was the first exercise of the § 801(d)(1) certification authority since the PDMA's enactment. The drug sample diversion provisions address a continuing enforcement challenge: FDA and DOJ regularly prosecute sample diversion cases where pharmaceutical sales representatives have stolen and resold drug samples. Recent rulemakings: 84 FR 46372 (September 2019) — finalized PDMA regulations after decades of partial implementation; 89 FR 14638 (February 2024) — FDA guidance on Florida wholesale importation program.

• 21 CFR Part 251 — Importation of Prescription Drugs (Section 804 Program) (FDA/CDER, 19 sections): the implementing regulations for FDCA § 804 (21 U.S.C. § 384), which authorizes the HHS Secretary to allow qualifying State and Tribal governments, pharmacies, and wholesalers to import certain prescription drugs from Canada when the Secretary certifies the program poses no additional risk to public health and safety and will result in significant savings to U.S. consumers. FDA finalized Part 251 in September 2020 (85 FR 62094) after more than 20 years of statutory authority going unimplemented. Key provisions:

  • § 251.2 — Eligible products: only prescription drugs in final dosage form manufactured at an FDA-inspected facility, approved in Canada by Health Canada, and with a U.S.-approved reference listed drug (RLD) equivalent are eligible; biological products, controlled substances, and infused, intravenous, inhaled, or parenteral drugs are explicitly excluded; the exclusions target the drug categories where supply chain integrity and identity verification are most difficult across international borders
  • § 251.3 — SIP Sponsor eligibility: only a State, Tribal, or territorial government (or a co-sponsor pharmacist or wholesaler working under a State SIP) may submit a Section 804 Importation Program (SIP) proposal; individual patients and private importers cannot submit SIP proposals; the State-sponsor structure creates government accountability for program safety and allows FDA to leverage state pharmacy regulatory infrastructure for oversight
  • §§ 251.10–251.11 — Foreign Seller and Importer registration: the Canadian Foreign Seller (the Canadian drug distributor or manufacturer) and the U.S. Importer (licensed wholesale drug distributor) must each register with FDA before conducting SIP transactions; registration requires: corporate identity, responsible individuals, facility addresses, proposed supply chain description, and agreement to FDA inspection; FDA may revoke registration for non-compliance
  • § 251.12 — Importer responsibilities: licensed importers under an approved SIP must: (a) purchase only from registered Foreign Sellers; (b) ensure each lot has passed qualifying laboratory testing before U.S. distribution; (c) maintain records sufficient to trace each product unit from Canadian manufacturer through U.S. distribution; (d) report adverse events and product defects to FDA within 15 days; (e) submit quarterly reports on import volumes and any supply chain irregularities
  • § 251.13 — Labeling requirements: imported drugs must be relabeled before U.S. distribution — Canadian labeling is not sufficient; relabeled products must meet all applicable U.S. drug labeling requirements (including Part 201 prescribing information for Rx drugs) and must include a statement identifying the product as imported under a Section 804 Importation Program; the relabeling requirement ensures U.S. pharmacists and patients receive familiar, FDA-compliant labeling rather than Canadian packaging
  • §§ 251.14 — Supply chain security: importers must maintain a complete, documented supply chain from Canadian point of manufacture through U.S. distribution; the supply chain documentation must allow FDA to trace any product unit back to its manufacturing lot within 48 hours; FDA may require electronic track-and-trace systems consistent with the Drug Supply Chain Security Act (DSCSA) requirements
  • §§ 251.15–251.16 — Qualifying laboratory testing: every imported lot must be tested by an ISO/IEC 17025-accredited laboratory before U.S. distribution; required tests include identity, purity, potency, and sterility (if applicable); the testing requirement ensures that drugs imported under SIP programs meet the same quality standards as domestically marketed drugs; lots that fail testing must be destroyed or re-exported and may not enter U.S. commerce; test records must be retained for 3 years and be available for FDA inspection
  • § 251.17 — Importation procedures: each SIP shipment must be accompanied by: the Foreign Seller's transaction history, the U.S. Importer's transaction statement, the qualifying lab test certificate of analysis, and the approved SIP proposal number; FDA district offices may examine or sample shipments at the port of entry; admissibility decisions apply to the lot, not just the sampled units
  • § 251.18 — Post-importation surveillance: importers must maintain a complaint file for SIP products, investigate all consumer complaints, and submit an annual safety report to FDA summarizing complaints, adverse events, and corrective actions; FDA may use post-importation surveillance data to modify or revoke a SIP approval
  • § 251.19 — Quarterly reporting: SIP Sponsors (States) must submit quarterly reports to FDA covering: total volume imported, number of lots tested and rejected, any supply chain interruptions, and estimated consumer cost savings; the reporting requirement provides FDA with the data to evaluate whether the statutory "significant savings" condition continues to be met

  The Section 804 program represents a narrow, tightly controlled exception to the PDMA's general reimportation prohibition — applicable only to Canadian drugs, only through State-sponsored programs, and only with extensive supply chain documentation and laboratory testing at every lot. As of 2026, Florida's SIP (approved January 2024) is the only operational program; Colorado, New Mexico, and several other states have submitted or are preparing SIP proposals. The program's long-term viability depends on maintaining adequate supply chain documentation across the Canadian border and on Canadian suppliers' willingness to participate despite potential contractual restrictions from brand manufacturers. Recent rulemakings: 85 FR 62094 (October 2020) — Part 251 final rule; 89 FR 3082 (January 2024) — FDA approval of Florida's SIP proposal (first operational Section 804 program).

• 21 CFR Part 510 — New Animal Drugs: General Provisions (FDA/CVM, 23 sections): the foundational administrative rules for the new animal drug program — companion to Part 514 (NADA applications) and Parts 520–526 (approved drug formulations). Part 510 establishes specific labeling requirements, addresses antibiotic use in food-producing animals, and creates the framework for import tolerances for residues of animal drugs not approved in the United States. Key provisions:

  • § 510.105 — Labeling of drugs for milk-producing animals: drugs intended for intramammary use in dairy cattle must bear labeling specifying that the drug cannot be used during the milk production period unless the label conditions include a milk withdrawal period; the requirement directly protects consumers from residues in commercially sold milk
  • § 510.106 — Labeling of antibiotics in milk-producing animals: antibiotic drugs used in milk-producing animals must carry label language stating that milk from treated animals should not be used for food during the withdrawal period and for a specified number of hours after treatment; the milk withdrawal period is one of the most consumer-safety-critical pieces of information on veterinary antibiotic labeling
  • §§ 510.110–510.112 — Antibiotics in food-producing animals: these sections document FDA's formal administrative rulings establishing that the agency has authority and responsibility to evaluate the public health impact of antibiotic use in food animals — the regulatory foundation for FDA's subsequent antimicrobial stewardship policies (Guidance for Industry #209 and #213), which asked drug sponsors to voluntarily remove growth promotion indications from medically important antibiotics and require veterinary oversight through VFDs (veterinary feed directives)
  • Subpart C (§§ 510.201–510.218) — Import tolerances for residues of unapproved new animal drugs: the framework allowing food imports that contain residues of animal drugs lawfully used in a foreign country but not approved by FDA. When a foreign government has approved an animal drug and established a safe residue tolerance, FDA may establish a corresponding import tolerance — permitting the food to enter U.S. commerce rather than being detained as adulterated. Petitions for import tolerances must include full safety data for human health evaluation; FDA evaluates import tolerance requests on the same science-based criteria as domestic approval. Without this mechanism, food imports from countries using different animal drug regimens would effectively be barred — a significant trade barrier

  Part 510's most consequential provisions in recent years are the antibiotic provisions (§§ 510.110–510.112), which formed the legal and policy foundation for FDA's 2012–2013 Guidance on Veterinary Oversight. No major amendments to Part 510 since 2003; the antibiotic stewardship changes were implemented through guidance rather than rulemaking.

• 21 CFR Part 514 — New Animal Drug Applications (NADA). The FDA Center for Veterinary Medicine (CVM) regulations implementing FDCA § 512 (21 U.S.C. § 360b), which requires approval of all drugs used in or on animals before commercial distribution — including drugs used in food-producing animals (cattle, swine, poultry, fish) where human consumers are exposed to drug residues through meat, milk, and eggs, and companion animal drugs used in dogs, cats, horses, and zoo animals. The NADA framework parallels the human NDA process but applies to the target animal species rather than humans, with additional requirements for food safety. Key provisions:

  • § 514.1 — Application contents: a full NADA must include: (a) safety and effectiveness data from adequate and well-controlled studies in the target animal species; (b) human food safety data for drugs used in food-producing animals — demonstrating that drug residues in edible tissue do not exceed the established tolerance or are safe at the expected residue level; (c) environmental impact assessment; (d) proposed labeling with conditions of use (species, indication, dose, route, withdrawal period); and (e) manufacturing information, including proposed specifications and analytical methods
  • § 514.105 — Approval regulation: when CVM approves a NADA, the Commissioner publishes a Federal Register regulation prescribing the conditions under which the drug may be used — including the target species, therapeutic indications, dosage form, administration route, and (for food animals) the withdrawal period — the minimum days between last drug administration and slaughter, milking, or egg collection to ensure residues fall below tolerance; unlike human NDAs, approval conditions are codified in the CFR (21 CFR Part 520 for oral drugs, Parts 522–526 for injectable and other formulations), creating binding conditions rather than just labeling requirements
  • § 514.106 — Supplemental applications: any change to an approved NADA that is a major change (new indication, new species, manufacturing process change) requires a supplemental application within 180 days; minor changes may be implemented with annual report notification; the distinction between major and minor changes parallels FDA's human drug supplement categories
  • § 514.110 — Grounds for refusal to file: FDA can refuse to file a NADA that lacks basic required information — missing safety sections, no clinical data from studies in the target species, or incomplete chemistry/manufacturing documentation; a refusal to file does not prevent resubmission
  • § 514.111 — 180-day review timeline: FDA must act on a filed NADA within 180 days — either approving, issuing a notice of opportunity for hearing on refusal to approve, or providing a written response identifying deficiencies; the 180-day clock is the regulatory commitment to CVM review speed
  • § 514.115 — Post-approval withdrawal: the Secretary may suspend approval of a NADA if new safety or efficacy evidence raises concerns — triggering an opportunity for hearing before final withdrawal; important for antimicrobial drugs in food animals where FDA has used withdrawal authority to address antibiotic resistance concerns
  • § 514.117 — Adequate and well-controlled studies: CVM applies the same scientific standard as the human drug program — studies must have a valid comparison treatment (placebo or active control), defined endpoints, and statistical analysis; for food animal efficacy, the studies must be conducted in the target commercial animal species under conditions resembling commercial use (not laboratory animals); for companion animals, the requirements mirror human clinical trial principles applied to the relevant species

  The NADA process governs two distinct regulatory concerns: veterinary therapeutic safety (the drug works and doesn't harm the animal) and human food safety (residues in meat, milk, or eggs don't harm people). The food safety requirement makes animal drug regulation uniquely connected to the food supply — a drug residue violation in food is a food safety problem, not just an animal health problem. The USDA's Food Safety and Inspection Service (FSIS) enforces the withdrawal periods established in approved NADAs through residue monitoring of slaughtered animals; violations are reported to FDA for NADA compliance action. Generic animal drugs are approved through the Abbreviated NADA (ANADA) pathway under § 514.1(b), which requires demonstrated bioequivalence to the reference listed drug rather than full safety/efficacy studies — the animal drug generic pathway mirrors the human ANDA framework. No major rulemakings since 2003 — the NADA framework has been stable while FDA's antimicrobial stewardship guidance (Guidance for Industry #209/213) has addressed antibiotic use in food animals through labeling changes rather than NADA regulatory amendments.

• 21 CFR Part 225 — Current Good Manufacturing Practice (cGMP) for Medicated Feeds: FDA's quality-system requirements for facilities that manufacture medicated animal feeds — animal feed products containing approved drugs (typically antibiotics, anthelmintics, or coccidiostats added at therapeutic or growth-promotion levels). Medicated feeds are a major drug delivery mechanism in commercial livestock operations — antibiotics fed to large poultry and swine flocks are distributed through feed mills rather than administered individually. Part 225 parallels the human drug cGMP requirements in Part 211 but is calibrated to the feed manufacturing context:

  • § 225.10 — Personnel: qualified, adequately trained supervisory personnel are essential; the regulation emphasizes that training must cover both feed manufacturing procedures and the specific drug being incorporated — the potency and safety of a medicated feed depends on accurate drug incorporation at the levels specified in the NADA approval
  • § 225.30 — Equipment: equipment must be designed to produce medicated feed at the intended drug potency and purity; scales and liquid metering equipment must be calibrated; equipment must be maintained in a clean and orderly condition — cross-contamination between drug types is a significant risk in mills that make multiple medicated feeds
  • § 225.42 / § 225.142 — Components: adequate procedures for identification, storage, and inventory control of all Type A medicated articles (concentrated drug premixes) and Type B medicated feeds (diluted premixes used in final feed); the Type A → Type B → Type C (finished medicated feed) dilution chain must be carefully controlled to ensure final drug concentration matches label claims
  • § 225.58 / § 225.158 — Laboratory controls: periodic assays of medicated feeds for drug component concentration; if assay results (including state feed control assays) show the feed is out of specification, the facility must investigate and correct; failed assays are a significant enforcement trigger
  • § 225.65 / § 225.165 — Equipment cleanout: adequate cleanout procedures for all equipment to avoid carryover contamination between drug types or between medicated and non-medicated feed; carryover of antibiotics into non-medicated feed can cause drug residue violations in animals that received supposedly drug-free feed
  • § 225.80 / § 225.180 — Labeling: labels must accurately identify the medicated feed, provide directions for use consistent with the approved NADA, and include the withdrawal period (the required drug-free period before slaughter); mislabeled medicated feeds are a major source of drug residue violations in the food supply

  Part 225 applies to all commercial feed mills that incorporate FDA-approved drug premixes into animal feed. The regulation's two structural tiers — Part 225 applies to commercial feed mills (Subpart A), and a lighter-touch "current practice" standard (Subpart B) applies to on-farm mixers who blend feed for their own animals — reflect the reality that most medicated feed is manufactured commercially. No major amendments since 1999 (64 FR 63203).

• 21 CFR Part 530 — Extralabel Drug Use in Animals: FDA's regulations implementing the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA), which for the first time explicitly authorized licensed veterinarians to prescribe and use approved animal or human drugs in an extralabel manner — that is, in a manner that departs from the approved labeling (different species, different dose, different indication, different route of administration). AMDUCA resolved a longstanding ambiguity: FDA's historical approval-based system theoretically made all off-label veterinary prescribing unlawful, even though it was routine practice essential to veterinary medicine:

  • § 530.3 — Definitions: "extralabel use" means actual or intended use of a drug in an animal in a manner not in accordance with the approved labeling; this includes use in a species not listed, at a dosage not specified, for an indication not approved, or via a route of administration not labeled
  • § 530.10 — Permitted extralabel use: an approved animal or human drug is not unsafe when used extralabel if: (a) there is a valid veterinarian-client-patient relationship (VCPR); (b) the veterinarian has determined that no approved animal drug will treat the condition; (c) the use does not result in violative drug residues; and (d) the prescribing veterinarian provides a label that includes the name and address of the veterinarian, the established name of the drug, directions for use, cautionary statements, and withdrawal period
  • § 530.20 — Food-producing animal conditions: when prescribing extralabel in food-producing animals, the veterinarian must determine the appropriate withdrawal period based on available information (including scientific literature); if no withdrawal data is available, the veterinarian must set a withdrawal period of zero — meaning the animal cannot be sent to slaughter until there is a scientific basis for a safe interval
  • § 530.21 / § 530.25 — FDA prohibitions: FDA may prohibit extralabel use of a drug in food-producing animals by order if the extralabel use creates a public health risk or results in residues that cannot be monitored with available analytical methods; FDA has prohibited extralabel use of several classes of drugs in food animals — including chloramphenicol, clenbuterol, diethylstilbestrol, and certain fluoroquinolones and glycopeptides
  • § 530.41 — Prohibited drugs list: a specific list of drugs prohibited from any extralabel use in animals (or in food-producing animals specifically); the list includes drugs with serious human food safety implications and those whose residues cannot be reliably detected below safe levels
  • § 530.5 — Veterinary records: as a condition of extralabel use, the veterinarian must keep records of extralabel uses that FDA may inspect; the recordkeeping requirement allows FDA to audit whether the VCPR and other conditions for permitted extralabel use were met

  Extralabel prescribing is a routine tool of veterinary medicine — companion animal veterinarians regularly prescribe human drugs for dogs and cats (where few animal drugs are approved), and food animal veterinarians use extralabel dosing when the approved drug regimen proves insufficient. Part 530's VCPR requirement is the load-bearing condition: the rule does not permit internet pharmacies or feed stores to sell drugs for self-prescribed extralabel use; all extralabel prescribing must flow through a licensed veterinarian who has examined the animal and established a professional relationship with the owner. No major amendments since 2003 (67 FR 5471).

How It Works

FDA is the gatekeeper for every drug sold in the United States — no new pharmaceutical product can reach patients without FDA approval, a process designed to ensure drugs are safe and effective before they reach the market.

Developing a new drug from discovery to market takes an average of 10–15 years and costs $1–2 billion. The path runs from preclinical laboratory and animal testing through an Investigational New Drug (IND) application authorizing human trials, then three phases of clinical trials — Phase I (20–100 healthy volunteers assessing safety and dosing), Phase II (100–500 patients assessing efficacy and optimal dose), Phase III (1,000–5,000 patients in confirmatory trials across diverse populations) — to a New Drug Application (NDA) compiling all clinical data, manufacturing information, and proposed labeling. The FDA then has a standard 10-month review window (6 months for priority review) before approving, rejecting, or requesting additional data, and Phase IV post-market surveillance tracks long-term safety in real-world populations after approval. For serious conditions with unmet medical needs, FDA offers four expedited programs: Fast Track (rolling review and frequent agency meetings), Breakthrough Therapy (intensive FDA guidance), Accelerated Approval (approval based on surrogate endpoints like tumor shrinkage, with post-market confirmatory trials required), and Priority Review (6-month instead of 10-month review clock). About half of novel drug approvals now use at least one expedited pathway.

The Drug Price Competition and Patent Term Restoration Act of 1984 — Hatch-Waxman — created the generic drug framework responsible for generics now accounting for roughly 90% of prescriptions filled in the United States. Generic manufacturers file Abbreviated New Drug Applications (ANDAs) demonstrating bioequivalence to the brand-name reference listed drug without new clinical trials. The FDA's Orange Book lists approved drugs and their patents; Paragraph IV patent challenges allow generics to enter before brand patents expire, with the first filer receiving 180 days of market exclusivity. FDA's safety mandate extends through the entire product lifecycle: Good Manufacturing Practice (GMP) regulations require quality control and validated processes, and FDA inspects approximately 3,000 drug manufacturing facilities per year — including foreign facilities that now account for roughly 40% of finished drug manufacturing and 80% of active pharmaceutical ingredient production. Risk Evaluation and Mitigation Strategies (REMS) restrict distribution or mandate patient monitoring for drugs with particular safety concerns. The Prescription Drug User Fee Act (PDUFA, first enacted 1992, reauthorized every five years) charges approximately $4.68 million per NDA (for applications requiring clinical data) in exchange for FDA performance commitments on review timelines — user fee revenue now funds over half of FDA's drug review activities, with parallel programs for generic drugs (GDUFA), biosimilars (BSUFA), and medical devices (MDUFA).

How It Affects You

If you take prescription drugs and want to understand your options: The FDA approval system shapes which drugs you can get, how quickly, and at what cost — more than most patients realize.

Generics and biosimilars: Generic drugs are the most important cost tool in the system. Generics contain the same active ingredient as the brand-name drug, at the same dosage and route, and are required to demonstrate bioequivalence (the same rate and extent of absorption). They are therapeutically equivalent for most purposes. Generics now account for approximately 90% of all prescriptions filled in the U.S. and save the healthcare system roughly $400 billion per year. If you're prescribed a brand-name drug, ask your pharmacist whether a generic is available — most states permit or require pharmacists to substitute a generic unless the prescriber writes "dispense as written."

For biologic drugs (complex protein-based medicines like Humira, Enbrel, and insulin): biosimilars are the generic equivalent, but they require separate demonstration of "no clinically meaningful differences" rather than simple bioequivalence. The biosimilar market has matured — Humira (adalimumab) alone has 10+ biosimilar competitors, and the savings opportunity is significant. Ask your doctor and insurer specifically about biosimilar options for any high-cost biologic you're prescribed.

Reporting adverse drug reactions: If you experience a side effect from a drug — especially one that's unexpected, serious, or not listed in the drug's labeling — report it through FDA's MedWatch program at fda.gov/safety/medwatch or by calling 1-800-FDA-1088. Your report becomes part of the FDA's post-market surveillance database and can contribute to safety signal detection that leads to label changes, new warnings, or market withdrawals. Health professionals are strongly encouraged to report; consumers can report directly too.

Drug shortages: The FDA maintains a current drug shortage database at fda.gov/drugs/drug-safety-and-availability/drug-shortages. If your pharmacy can't fill your prescription, check the shortage list — FDA posts the reason for the shortage, anticipated resolution date, and information on alternatives. For critical medications with no alternatives, your prescriber can contact the drug manufacturer directly or contact FDA's drug shortage staff.

If you're a patient with a serious or life-threatening condition exploring pre-approval access: Three distinct legal pathways exist for accessing drugs that haven't completed the approval process:

(1) Clinical trials: The most structured path. Participation in Phase II or III trials gives you access to the investigational drug while contributing to the evidence base for approval. Search at clinicaltrials.gov — filter by condition, location, and study status. "Recruiting" trials are actively enrolling. Some trials compensate participants; all provide the drug at no cost. Discuss eligibility with your physician — medical exclusion criteria are strict.

(2) Expanded Access (Compassionate Use): Under 21 C.F.R. Parts 312.300-312.320, FDA can permit use of an investigational drug outside a clinical trial for a patient with a serious condition who has no comparable alternative. Your physician must apply directly to the drug manufacturer (who can say no) and to FDA. FDA approves the vast majority of expanded access requests — the bottleneck is often the manufacturer's willingness to participate. The FDA's expanded access information page at fda.gov/patients/learn-about-expanded-access-and-other-treatment-options explains the process.

(3) Right to Try (21 U.S.C. § 360bbb-0a, enacted 2018): Allows terminally ill patients who have exhausted approved options to access drugs that have completed Phase I clinical trials. Unlike Expanded Access, Right to Try doesn't require individual FDA authorization for each patient — just manufacturer approval. The practical limitation: most manufacturers are reluctant to provide access outside formal expanded access programs due to liability and drug supply concerns.

If you're a pharmaceutical company or biotech startup: The NDA/ANDA process is the central regulatory pathway, but the strategic choices around it determine commercial success.

Expedited pathways — Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review — are not just speed enhancements; they represent materially different FDA relationships. Breakthrough Therapy designation is particularly valuable: it brings intensive FDA senior staff involvement, more frequent meetings, and commitment to resolve issues before NDA submission rather than during review. Apply for Breakthrough designation early (during Phase II if possible) if your drug shows large preliminary efficacy. The request can be made at any time, but earlier is better.

Patent and exclusivity strategy under Hatch-Waxman determines when you face generic competition. Brand drugs get 5 years of new chemical entity (NCE) exclusivity (no generics during this period) or 3 years of exclusivity for new clinical studies for existing compounds. Pharmaceutical manufacturers routinely list additional patents in the Orange Book to maximize the period before generic entry — courts have found some of these listings abusive. Generic manufacturers can challenge listed patents via Paragraph IV certifications; the first generic filer that successfully challenges gets 180 days of generic exclusivity — a massive incentive for Paragraph IV challenges.

PDUFA user fees — approximately $4.68 million per NDA application (plus separate fees for manufacturing facilities and approved products) — are substantial but buy FDA performance commitments. FDA must act on a standard NDA within 10 months and a priority NDA within 6 months. If FDA doesn't meet its PDUFA goal date, you have grounds to escalate internally. Understanding FDA's review clock (starting from the date FDA receives and files your application) is essential for launch planning.

If you're focused on drug pricing: FDA's generic approval system is the most powerful drug price reduction mechanism available in the U.S. — more predictable than legislative negotiation and grounded in durable market competition. For any high-cost drug, checking the FDA Orange Book (accessdata.fda.gov/scripts/cder/ob) reveals when patents expire, what patents remain listed, and whether generic applications have been filed. Generic filing (ANDA submission) is publicly visible in FDA databases, giving early warning of upcoming price competition.

The Inflation Reduction Act's Medicare drug price negotiation — which allows CMS to directly negotiate prices for a set of high-cost drugs without generic competition — is a supplement to, not a replacement for, the Hatch-Waxman generic system. For the highest-cost Medicare drugs that lack generic competition, IRA negotiation provides a mechanism for price reduction that doesn't depend on patent expiration timelines.

If you're concerned about drug prices: FDA's generic approval process is the primary mechanism for drug price competition — generics save the U.S. healthcare system ~$400 billion per year. Biosimilar approval (under the BPCIA) provides a pathway for competition with biologic drugs. The Inflation Reduction Act's Medicare drug price negotiation (separate from FDA) directly addresses prices for high-cost drugs.

Implementing Regulations — Clinical Investigator Financial Disclosure and Off-Label Promotion

• 21 CFR Part 54 — Financial Disclosure by Clinical Investigators (FDA — requires applicants to disclose financial interests held by clinical investigators who conducted studies submitted in marketing applications for drugs, biologics, and devices; the rule is designed to ensure FDA reviewers know when study investigators had a financial stake in the outcome):

  • § 54.2 — Definitions: "compensation affected by the outcome" means compensation that would be higher for a favorable outcome than for an unfavorable outcome — including milestone payments contingent on study success, and royalty arrangements tied to approval; "significant equity interest" means any ownership interest worth more than $50,000 in the public or private company whose product is being studied
  • § 54.4 — Certification and disclosure: for each clinical study submitted in a marketing application, the applicant must provide to FDA either: (1) a certification that the investigator had no financial arrangements requiring disclosure, or (2) a disclosure statement describing the specific financial arrangements; the investigator list must cover all clinical investigators who conducted the covered study — not just the principal investigator but all sub-investigators identified in the study protocol
  • § 54.5 — Agency evaluation: when disclosure statements reveal significant financial arrangements, FDA evaluates whether those arrangements created a potential bias in study design, conduct, or reporting; FDA considers whether the investigator had statistical control over the data, whether blinding procedures adequately controlled for bias, and whether independent monitors verified data integrity; a study with disclosed financial conflicts is not automatically rejected — FDA assesses whether the conflict compromised the study's reliability, and may request additional studies or impose labeling to reflect the limitation
  • § 54.6 — Record retention: the applicant must retain financial disclosure records and make them available for FDA inspection for 2 years after the date of approval or, if the application is rejected, for 2 years after the rejection; investigators' financial records related to covered studies must also be retained and made available to the applicant for submission; this creates a documentary chain from the investigator's financial relationship to the marketing application and its review record

  Part 54's financial disclosure framework responds to documented cases where investigators with undisclosed equity stakes in drug companies conducted clinical trials for those companies and reported favorable results that subsequent studies could not replicate. The rule does not prohibit financial relationships between investigators and sponsors — academic medical centers routinely receive research funding from the companies whose drugs they study — but requires transparency so that FDA review accounts for the potential bias. The $50,000 equity threshold, set in 1998, has not been adjusted for inflation and is widely criticized as too low to capture many significant financial interests in an era when pharmaceutical company shares can move dramatically on FDA decisions.

• 21 CFR Part 99 — Dissemination of Information on Unapproved/New Uses for Marketed Drugs, Biologics, and Devices (FDA — the regulatory framework governing when and how pharmaceutical manufacturers may distribute peer-reviewed scientific literature about unapproved ("off-label") uses of their FDA-approved products to physicians and other health care professionals):

  • § 99.101 — Information that may be disseminated: a manufacturer may distribute written information about a safety, effectiveness, or benefit of an unapproved use of an approved drug or device only if the information is (1) an unabridged reprint or copy of a peer-reviewed article from a journal that applies bona fide expert peer review; or (2) a reference publication — such as a medical textbook — published by an independent publisher; the manufacturer may not modify the article or add promotional language; the article must be accompanied by mandatory disclosure statements
  • § 99.103 — Mandatory statements: any information disseminated under Part 99 must prominently display: a statement identifying the information as concerning a use not approved in the current labeling; any clinical investigator financial disclosures associated with the study; and the most recent FDA-approved labeling for the product, including information about approved uses; the disclosures ensure physicians understand that the disseminated information goes beyond what FDA has approved
  • § 99.105 — Permitted recipients: manufacturers may only provide the off-label information to health care practitioners, pharmacy benefit managers, health insurance issuers, group health plans, drug information centers, and peer-review bodies; direct-to-consumer promotion of off-label uses is not permitted under Part 99
  • § 99.201 — Pre-dissemination submission: 60 days before disseminating any off-label information under Part 99, the manufacturer must submit the information to FDA along with a description of the intended use, the bibliography of the article, any supplementary materials, and a copy of the current labeling; FDA reviews the submission but does not pre-approve or prohibit dissemination — the rule creates a notice mechanism, not a pre-clearance requirement
  • § 99.203 — Supplement obligation: the manufacturer must commit to submitting a supplemental application to FDA for approval of the off-label use within a specified period of time after distributing information about it; this "pursue approval" obligation is the key trade-off — the manufacturer gets to distribute information about unapproved uses in exchange for a commitment to actually pursue approval, which would benefit patients who currently access the use without FDA review of the safety/efficacy data

  Part 99's framework reflects the tension between FDA's approval mandate (information about unapproved uses should come only after FDA review) and the clinical reality that physicians routinely prescribe drugs for uses not listed in the label — and need access to the scientific literature supporting those uses. The First Amendment has constrained FDA's ability to restrict truthful off-label promotion: the Second Circuit's decision in United States v. Caronia (2012) held that FDA could not criminally prosecute a drug company sales representative for truthful off-label promotion. Since then, FDA has navigated an evolving legal landscape around off-label communications, and Part 99's framework has been updated to focus on publication-based dissemination (the most defensible form of off-label communication) rather than broad prohibition of all off-label promotion.

State Variations

Drug approval is exclusively federal (FDA). However:

• State pharmacy boards regulate dispensing, substitution, and pharmacy practice
• State laws on generic substitution vary — most allow or require pharmacists to substitute generics unless the prescriber indicates "dispense as written"
• State drug importation programs (from Canada) have been authorized by federal law but implementation has been limited
• State pharmaceutical pricing transparency laws and PBM regulation are growing areas of state activity

Pending Legislation

• S 3122 — Better FDA Act. Requires FDA review of substances classified as "generally recognized as safe" (GRAS), closing the self-certification loophole for food additives. Status: Introduced.
• S 3510 — Biosimilar Inspection Modernization Act. Streamlines FDA inspection procedures for biosimilar manufacturing facilities. Status: Introduced.
• HR 5526 / S 1954 — Biosimilar Red Tape Elimination Act. Reduces regulatory barriers to biosimilar approval and market entry. Status: Introduced.
• HR 2821 — FDA Modernization Act 3.0. Expands alternatives to animal testing in drug development, building on the 2022 FDA Modernization Act. Status: Introduced.
• S 1414 — Expedited Access to Biosimilars Act. Accelerates the approval pathway for biosimilar drugs. Status: Introduced.
• S 1302 — Increasing Transparency in Generic Drug Applications Act. Requires greater disclosure in the ANDA filing process to reduce gaming and delay tactics. Status: Introduced.
• S 1096 — Preserve Access to Affordable Generics and Biosimilars Act. Targets pay-for-delay settlements between brand and generic drug manufacturers. Status: Introduced.

Recent Developments

• FDA has approved a growing number of AI/ML-enabled medical products and is developing regulatory frameworks for AI in drug development (adaptive clinical trials, real-world evidence, digital biomarkers)
• Accelerated approval reform has increased — FDA has withdrawn several accelerated approvals where post-market confirmatory trials failed, strengthening the program's credibility
• Drug shortages remain a persistent challenge, with FDA maintaining an active shortage list and working to diversify pharmaceutical supply chains away from concentrated foreign manufacturing
• In March 2026, the FDA published revised draft guidance (Revision 4) on biosimilar development under the Biologics Price Competition and Innovation Act (BPCI Act), updating Q&As for industry on the abbreviated biosimilar approval pathway.
• The biosimilar market has matured significantly, with multiple biosimilars available for high-cost biologics (adalimumab/Humira alone has 10+ biosimilar competitors), though uptake varies
• In March 2026, FDA withdrew approval of 46 new drug applications (NDAs) from multiple applicants after the applicants notified the agency that the drug products were no longer marketed.
• Also in March 2026, FDA published draft guidance on 'Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection,' providing guidance for foreign and domestic manufacturers on responding to current good manufacturing practice inspection findings.
• In early March 2026, FDA announced a public workshop on FY2026 Generic Drug Science and Research Initiatives and published additional draft and revised product-specific guidances for bioequivalence study design.
• In February 2026, FDA revoked its methods of analysis regulation and also revoked regulations regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports with the European Community, streamlining the regulatory framework. FDA also published modifications to its recognized standards list (Recognition List Number 065) under FDAMA 1997.
• In February 2026, FDA issued a priority review voucher for ZEVASKYN (prademagene zamikeracel) as a rare pediatric disease product, and determined that TOLECTIN DS (tolmetin sodium) was not withdrawn from sale for safety or effectiveness reasons.

In January 2026, FDA announced draft guidance on records access authority for cosmetics under the MoCRA (Modernization of Cosmetics Regulation Act of 2022), establishing the agency's framework for accessing cosmetic manufacturers' records.

• In January 2026, FDA issued priority review vouchers for rare pediatric disease products KYGEVVI (doxecitine/doxribtimine) and RHAPSIDO (remibrutinib), and published draft guidance on minimal residual disease and complete response as endpoints for accelerated approval in multiple myeloma. FDA also issued emergency use authorizations for COVID-19 medical devices and published draft ICH M4Q(R2) guidance on the Common Technical Document for pharmaceutical registration.
• A March 2026 Politico report highlighted the FDA's limited authority over pharmaceutical advertising, noting the agency cannot restrict the amount companies spend on prescription drug TV ads — a topic of renewed debate under HHS Secretary Kennedy's push to reform drug marketing practices.
• In March 2026, the Trump administration announced negotiated discounts with Novo Nordisk and Eli Lilly on GLP-1 receptor agonist obesity drugs, representing a direct government intervention in pharmaceutical pricing outside the traditional Medicare negotiation framework.
• In February 2026, President Trump launched TrumpRx.gov, a public-facing platform designed to publicize negotiated drug price discounts and direct patients to lower-cost pharmaceutical options — a novel use of executive messaging to pressure drug pricing transparency.